Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IQWiG Backs Novartis’ Jetrea, Drops Almirall’s Constella On Same Day

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s IQWiG has backed Novartis’ Jetrea for VMT, albeit with restricted indication, but knocked back Almirall’s Constella, citing study irrelevance.

Advertisement

Related Content

Linzess Continues On Strong Launch Trajectory, Says Ironwood/Forest
Novartis Triumphs At EMA With Jetrea, But Merck Has Suspension of Three Merck Products Confirmed
Signifor Approval Highlights Success Of Novartis’ Parallel Development Strategy
ThromboGenics Takes Its Time On Solo Launch Of Eye Drug Jetrea
New Irritable Bowel Disease And Burn Therapies Among Those Recommended By Europe’s CHMP

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel